# Precision BioSciences Reports First Quarter 2026 Financial Results and Provides Business Update
Canonical URL: https://biopharmsignal.com/news/DTIL/precision-biosciences-reports-first-quarter-2026-financial-results-and-provides-business-update
Ticker: DTIL
Company: Precision BioSciences
Source: Precision BioSciences
Published: 2026-05-05 11:01 EST
Original Source URL: https://investor.precisionbiosciences.com
## Summary

- Continued advancement of the Phase 1/2a ELIMINATE-B trial of PBGENE-HBV across multiple dosing cohorts; Late-Breaking poster presentation for PBGENE-HBV accepted at European Association for the Study of the Liver Congress 2026 - - Advanced PBGENE-DMD toward clinical evaluation in the Phase 1/2

## Article Body
- Continued advancement of the Phase 1/2a ELIMINATE-B trial of PBGENE-HBV across multiple dosing cohorts; Late-Breaking poster presentation for PBGENE-HBV accepted at European Association for the Study of the Liver Congress 2026 - - Advanced PBGENE-DMD toward clinical evaluation in the Phase 1/2
## Recent Company News
- 2026-05-27 06:30 EST — [Precision BioSciences Announces New and Late-Breaking PBGENE-HBV Clinical Data from the ELIMINATE-B Study at European Association for the Study of the Liver Congress 2026](https://biopharmsignal.com/news/DTIL/precision-biosciences-announces-new-and-late-breaking-pbgene-hbv-clinical-data-from-the-eliminate-b-study-at-european-association-for-the-study-of-the-liver-congress-2026) — Source: Precision BioSciences
- 2026-05-21 11:01 EST — [Precision BioSciences to Host Investor Webcast to Discuss Late-Breaking PBGENE-HBV Data from ELIMINATE-B Trial Presented at European Association for the Study of the Liver Congress 2026](https://biopharmsignal.com/news/DTIL/precision-biosciences-to-host-investor-webcast-to-discuss-late-breaking-pbgene-hbv-data-from-eliminate-b-trial-presented-at-european-association-for-the-study-of-the-liver-congress-2026) — Source: Precision BioSciences
- 2026-05-14 11:01 EST — [Precision BioSciences Presents New Preclinical Data Supporting the Advancement of PBGENE-DMD into Clinic at the American Society of Gene & Cell Therapy 2026 Annual Meeting](https://biopharmsignal.com/news/DTIL/precision-biosciences-presents-new-preclinical-data-supporting-the-advancement-of-pbgene-dmd-into-clinic-at-the-american-society-of-gene-and-cell-therapy-2026-annual-meeting) — Source: Precision BioSciences
- 2026-05-05 11:01 EST — [Precision BioSciences Reports First Quarter 2026 Financial Results and Provides Business Update](https://biopharmsignal.com/news/DTIL/precision-biosciences-reports-first-quarter-2026-financial-results-and-provides-business-update) — Source: Precision BioSciences
- 2026-04-30 11:01 EST — [Precision BioSciences to Report First Quarter 2026 Financial Results on May 5, 2026](https://biopharmsignal.com/news/DTIL/precision-biosciences-to-report-first-quarter-2026-financial-results-on-may-5-2026) — Source: Precision BioSciences
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)